At the heart of this breakthrough lies a meticulous design strategy that leverages the unique properties of macrophages—immune cells notorious for their phagocytic capabilities, which enable them to engulf pathogens and cellular debris. By harnessing these cells’ innate functions, the research team has endowed phagobots with the extraordinary ability to not only traverse cellular environments autonomously but also to carry out targeted destruction of harmful materials. The integration of light-powered propulsion systems turns these biological machines into active agents capable of controlled movement without the need for external mechanical parts, reducing the risk of immune rejection or toxicity.

One of the most compelling aspects of the phagobot technology is its reliance on light as an energy source. Utilizing specific wavelengths, these microrobots are activated and guided, enabling on-demand control over their movement and function. This method sidesteps the limitations of chemical fuels, which often introduce complications in biological settings. The use of light provides a non-invasive, highly tunable stimulus that can penetrate deep enough into tissues to direct the microrobots while minimizing collateral damage to surrounding cells. This precision is vital in applications such as targeted drug delivery and clearing diseased or necrotic tissues.

The engineering of the phagobot involved delicate cellular manipulations to confer them with photoreactive capabilities. This was achieved by integrating nanoscale photosensitive materials within the membranes of macrophages, effectively turning these immune cells into microscopic robots responsive to external light cues. When illuminated, these materials induce localized biochemical reactions that generate propulsion forces, allowing the phagobots to swim, steer, and adjust their velocity within fluidic biological environments. This transformation from a passive phagocyte into an agile microrobot is a feat of multidisciplinary innovation combining cell biology, materials science, and photonics.

In vitro experiments with phagobots demonstrated remarkable dexterity in movement and the ability to selectively phagocytose target particles, including bacterial pathogens and synthetic debris mimicking diseased tissues. By illuminating the microrobots with controlled light patterns, the researchers successfully navigated them through microscopic mazes and fluid channels, mimicking the complex vasculature of human tissues. The phagobots exhibited targeted accumulation in predesignated areas, showcasing their potential for site-specific therapeutic interventions that minimize systemic side effects and enhance treatment efficacy.

The transition from in vitro to in vivo studies marked a critical milestone. Upon injection into animal models, phagobots retained their mobility and phagocytic function within living organisms, overcoming biological barriers that often hinder microrobot navigation. Their biocompatibility was a significant advantage, as these cellular machines are less likely to provoke adverse immune responses compared to synthetic counterparts. Fluorescence imaging and histological analyses confirmed the microrobots’ capacity to home in on sites of infection or inflammation, providing a promising platform for the development of targeted immunotherapies and pathogen clearance mechanisms.

Beyond infection control, the phagobot technology holds transformative potential for tackling cancerous tissues. Tumors often create immunosuppressive microenvironments, making it challenging for conventional therapies to be effective. Phagobots, armed with their ability to recognize and engulf abnormal cells, could be programmed to discriminate malignant from healthy cells, delivering cytotoxic payloads precisely where needed. Furthermore, their light-responsive propulsion ensures versatile maneuverability, allowing deep penetration into tumor masses that are typically difficult for drugs to reach, thereby overcoming one of oncology’s longstanding hurdles.

The modular nature of phagobot design also permits a high degree of customization. By varying the type of light-sensitive nanomaterials and adjusting illumination parameters, the researchers can fine-tune phagobot behavior—including speed, directionality, and phagocytic activity. This adaptability opens avenues for personalized medicine, tailoring microrobot functions to the specific needs of individual patients or disease states. The integration of biosensors within phagobots further enables real-time monitoring of their environment, providing critical feedback that can be used to optimize therapeutic outcomes dynamically.

Safety remains paramount in the advancement of any biomedical technology, and the phagobot development is no exception. Comprehensive toxicity assays demonstrated that the light intensities employed do not induce significant tissue damage or cellular stress, making the approach highly compatible with living systems. Moreover, since the phagobots are derived from native immune cells, they exhibit natural degradation pathways, mitigating concerns about accumulation or long-term persistence. The researchers emphasize that ongoing work aims to establish robust protocols for clearance and control post-treatment to ensure patient safety.

The integration of phagobot technology with existing medical equipment holds promise for clinical translation. For example, coupling these microrobots with endoscopic light delivery systems could allow physicians to precisely deploy and guide them during minimally invasive procedures. Additionally, the ability to remotely activate phagobots using external light sources means that patients could potentially receive treatments without extended hospital stays, heralding a new frontier in outpatient care and telemedicine. The versatility and user-friendly nature of the system bode well for future scalability and widespread adoption.

Challenges remain, of course, in scaling production and ensuring consistent functionality across batches of phagobots. The manufacturing process requires tight control over cellular modifications and material integration to preserve cell viability and responsiveness. The research team is exploring automated biofabrication techniques and advanced quality control measures to address these concerns. Moreover, regulatory pathways for cellular microrobots are still nascent, necessitating thorough documentation of safety and efficacy to obtain approvals. Nonetheless, the demonstrated success in preclinical models provides a strong foundation for optimistic progress.

The conceptual leap represented by the phagobot underscores a broader trend in nanomedicine: the integration of living cells as active components in therapeutic devices. Unlike traditional synthetic nanocarriers, these hybrid systems capitalize on biological intelligence and adaptability, offering dynamic responses to complex physiological cues. As the repertoire of biological microrobots expands, new horizons in disease diagnosis, targeted therapy, and regenerative medicine emerge, driven by the unique synergy of nature and technology.

Looking forward, the researchers envision expanding phagobot capabilities beyond phagocytosis to encompass drug nanocarrier functions, genetic modification delivery, and immune modulation. Incorporating artificial intelligence algorithms to autonomously navigate complex environments or respond to biochemical signals could further enhance their utility. As this field progresses, the ethical and societal implications will likewise need careful consideration, ensuring that the deployment of living microrobots aligns with safety standards and public trust.

In conclusion, the advent of light-powered phagocytic macrophage microrobots marks a seminal advancement in biomedical technology, combining cellular biology’s sophistication with cutting-edge engineering to create novel therapeutic agents. Their demonstrated effectiveness both in vitro and in vivo paves the way for revolutionary strategies in combating infections, cancer, and other diseases resistant to conventional approaches. As the research community builds upon these foundational achievements, the vision of intelligent, autonomous microrobots operating within the human body moves closer to reality, promising transformative impacts on healthcare and beyond.

—

Subject of Research: Development and application of light-powered phagocytic macrophage microrobots for targeted biomedical interventions.

Article Title: Light-powered phagocytic macrophage microrobot (phagobot): both in vitro and in vivo.

Article References:
Li, X., Zhong, S., Pan, T. et al. Light-powered phagocytic macrophage microrobot (phagobot): both in vitro and in vivo. Light Sci Appl 14, 202 (2025). https://doi.org/10.1038/s41377-025-01881-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41377-025-01881-3

Traditional techniques for inducing polymerization—or the chemical linking of small molecular units known as monomers to create polymers—inside living tissue have been severely limited by the penetration depth of their activating signals. Previous efforts predominantly relied on infrared (IR) light to trigger this process, but IR light scarcely reaches beyond superficial layers beneath the skin. The Caltech team’s novel approach overcomes this fundamental challenge by harnessing ultrasound, a modality long valued in medical imaging for its noninvasive ability to reach deep tissue depths. The new technique enables precise spatial control, deep inside the body, of where polymers form, all while preserving biocompatibility essential for medical applications.

The foundational concept centers on the use of low-temperature-sensitive liposomes—tiny spherical vesicles comprising protective lipid bilayers—that are well known as carriers in drug delivery systems. By encapsulating crosslinking agents inside these lipid spheres and embedding them in a polymer solution containing the desired monomers, scientists created a composite bioink suitable for direct injection into living tissue. This bioink also contains an imaging contrast agent, specifically gas vesicles derived from bacteria, which serve a dual purpose: they appear clearly in ultrasound imaging and undergo a detectable contrast change upon polymerization, allowing researchers to visualize in real time the spatial and temporal dynamics of the printing process inside the body.

The magic happens when focused ultrasound waves are applied to a defined region, raising the temperature of that microenvironment by a mere 5 degrees Celsius. This seemingly small thermal perturbation is enough to cause the liposomes to release the crosslinking agents, thereby initiating polymerization exclusively in that localized area. The result is an in situ formation of polymer structures—solid, stable networks—directly within targeted tissue, marking a significant advancement beyond surface-level polymer printing or drug delivery. Importantly, this thermo-responsive mechanism ensures that polymer formation is controlled both temporally and spatially, mitigating unintended or off-target effects that often hamper other delivery methodologies.

The researchers named this platform the Deep Tissue In Vivo Sound Printing (DISP) system, an apt descriptor reflecting its ability to “print” inside the living body using sound. The method’s flexibility extends beyond printing simple polymers, enabling the fabrication of complex bioadhesive gels for wound sealing, drug-loaded hydrogels for localized chemotherapy, and even bioelectric hydrogels embedded with conductive nanomaterials such as carbon nanotubes or silver nanoparticles. These electrically conductive hydrogels can potentially interface with biological systems to monitor physiological signals, for example, capturing cardiac activity much like an internal electrocardiogram.

In preclinical experiments with murine models, DISP has demonstrated remarkable efficacy. When hydrogels loaded with doxorubicin—a widely used chemotherapeutic agent—were printed near bladder tumors, researchers observed significantly increased tumor cell death over several days, outperforming traditional methods of drug delivery involving direct injection. This validates not only the precision and localization of the approach but also its capacity to enhance therapeutic outcomes by maintaining high local drug concentrations while minimizing systemic exposure. These encouraging results warrant further investigation into scaling the platform for larger animal models and, eventually, clinical trials in humans.

A key enabler of the DISP platform’s accuracy is the use of bacterial gas vesicles as ultrasound contrast agents. These hollow protein nanostructures dramatically enhance the ability of ultrasound imaging to detect polymerization events in real time. Upon the chemical crosslinking of monomers into a gel network, the gas vesicles undergo structural changes that alter their acoustic properties. This shift is detected as a contrast change in ultrasound images, effectively providing a molecular “signal” that researchers can use to monitor the formation and architecture of printed polymers noninvasively. Such imaging feedback is critical to precisely applying the focused ultrasound, ensuring that printing remains confined to intended regions within dynamic biological environments.

The research team, led by Wei Gao, Professor of Medical Engineering at Caltech, envisions future iterations of the DISP platform augmented by artificial intelligence and machine learning algorithms. These enhancements could enable autonomous, high-precision ultrasound targeting in complex, moving organs such as the beating heart. Integrating automated feedback loops with ultrasound imaging and printing controls could facilitate adaptive, real-time tuning of printing parameters, overcoming challenges posed by intrabody motion and physiological variability. The potential to deploy such “smart” sound printing in living patients promises to accelerate translation of this cutting-edge technology from bench to bedside.

Besides the therapeutic benefits, DISP opens exciting avenues in regenerative medicine and bioelectronics. By printing cells embedded within hydrogels directly at injury sites, the technology could stimulate tissue regeneration with unparalleled spatial accuracy. Meanwhile, printed bioelectronic interfaces crafted in vivo could provide novel means of continuous physiological monitoring or neuromodulation, potentially ushering in new classes of implantable medical devices that self-assemble within the body without invasive surgery.

The multidisciplinary nature of this breakthrough touches upon fields ranging from chemical engineering and materials science to biomedical engineering and medical imaging. The collaborative team included experts from Caltech, the University of Utah, UCLA, USC, and the Terasaki Institute for Biomedical Innovation, demonstrating the power of cross-institutional cooperation in tackling complex biomedical challenges. Supported by several major funding agencies, including the National Institutes of Health and the American Cancer Society, this research represents a significant convergence of innovative materials, imaging contrast agents, and applied physics.

As the next steps, the research team plans to test the DISP system in larger animal models to evaluate the scalability and safety of the method in anatomies more comparable to humans. Moreover, they aim to refine the bioink formulations to optimize biocompatibility, mechanical properties, and functional payload delivery. The integration of AI-driven ultrasound control is anticipated to drastically improve the precision and usability of the platform in clinical settings, holding promise for personalized therapies, minimally invasive surgeries, and localized treatments for a range of diseases.

In summary, the development of the Deep Tissue In Vivo Sound Printing platform is a landmark achievement that redefines the frontiers of in vivo 3D printing and targeted drug delivery. By utilizing focused ultrasound to trigger polymerization within living tissue, the technology overcomes previous depth limitations and opens a new paradigm for printing functional materials directly inside the body. The ability to visualize and control this process in real time adds an unprecedented level of precision, suggesting a future where patients might receive personalized, on-demand treatments with minimal side effects. As this sound-based printing technology matures, it holds transformative potential not just for cancer therapies but also for regenerative medicine, wound healing, and bioelectronic interfaces, promising a new era of medical innovation.

Subject of Research: Deep tissue in vivo 3D printing, ultrasound-triggered polymerization, targeted drug delivery, bioadhesive gels, bioelectric hydrogels.

Article Title: Imaging-guided deep tissue in vivo sound printing

News Publication Date: 8-May-2025

Web References: http://dx.doi.org/10.1126/science.adt0293

Image Credits: Elham Davoodi and Wei Gao

Keywords: Polymers, Drug delivery systems, Targeted drug delivery, Regeneration, Ultrasound